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Editorial
What is the impact of sentinel node biopsy
in the management of cancer?
Sentinel node biopsy (SNB) is a surgical/histopathological
diagnostic tool that is increasingly used but still being evalu-
ated in surgical oncology.
The concept of sentinel node biopsy (SNB) was first estab-
lished in melanoma of the skin [1]. It is based on the obser-
vation that from a given area of the skin, lymphatic spreading
of melanoma cells proceeds following sequential steps, in an
orderly fashion. The first lymph node encountered by floating
melanoma cells is called the sentinel node (SN) and SN is
specifically (95%) the site of micrometastases if they exist. In
case of unpalpable regional lymph node (N0), the histological
status of the sentinel node is a prognostic criterion superior—
in multivariate analysis—to Breslow’s thickness [2].
Survival correlates with the size of lymph node metastasis.
Roughly, one single palpable lymph node (N2) results in
5-year survival of 50%, one sentinel node (N1) histologically
invaded, 5-year survival of 60%, and one sentinel node (N0)
not histologically invaded but PCR positive, 5-year survival of
70%. There is still a debate on the therapeutic value of SNB
in melanoma. Indeed, the better survival of patients with early
diagnosis of lymph node metastasis followed by selective
lymph node dissection (SLND) can be interpreted as the result
of better tumour eradication compared with a watch-and-wait
policy that consists of doing a radical lymph node dissection
when lymph node metastases appear clinically. However, ran-
domized trials in high risk primary melanoma comparing
immediate elective lymph node dissection (ELND) to deffered
complete lymph node dissection (CLND) -that is when palp-
able metastatic node appeared- failed to show any difference
in overall survival. However, SN is not the exclusive site of
micrometastases. If one considers the first metastatic events
occurring within 5 years of adequate removal of high risk—
>1.5mm thickness—primary melanoma, only 20–30% will
appear in regional lymph nodes, 8–10% as in transit and 20–
40% as distant metastases. This means that the status of SN is
a window on the metastatic potential of the melanoma that is
also correlated with metastases at other sites, in case of posi-
tivity. The Sydney Melanoma Unit reviewed 836 SNB-nega-
tive melanoma patients. With a median of 42.1 months,
melanoma specific survival at 5 years was 90%, compared
with 56% for SN-positive patients (P<0.001). Eighty-three
patients with negative SNB (9.9%) had a recurrence. Twenty-
seven patients developed recurrence in the regional node field,
and in 22 of these, it was the first recurrence site. Six devel-
oped local recurrence, 17 an in-transit metastasis, and 58 dis-
tant disease. The false-negative rate was then 13.2%. A very
recent third interim analysis of a worldwide randomized trial,
the Mslt-1 trial, on SNB shows that melanoma patients who
had wide excision followed by SLND (n= 1204) had a survi-
val similar to patients where a watch-and-wait policy had
been followed (n = 797), with CLND in case of pathological
lymph node development [3]. In this study, the disease free
survival was superior after SNB [4].
A recent study on 146 high risk primary melanoma cases
demonstrated that the metastatic deposits in the SN were sub-
capsular in 26.0% of patients. None of these patients had any
sentinel nodes involved on CLND. In the patients whose senti-
nel node metastases had a different microanatomic location,
the rate of no sentinel node involvement was 22.2% overall.
The authors concluded that in patients with only subcapsular
deposits in the SN, it is possible that CLND could safely be
avoided [5].
Therefore, we can consider SNB as a diagnostic tool with
an acceptable false negative rate that detects early lymph node
metatases, a clinical condition that appears optimal for adju-
vant immunotherapy protocols [6, 7].
Historically, the second indication was breast cancer where
SNB appeared useful for the selection of patients to adjuvant
treatment with a method that avoids the sequellae of axillary
dissection such as oedema [8, 9]. In the management of breast
cancer, systemic treatment has a proven impact on survival, in
contrast to melanoma. In case of positive SNB, the consensual
attitude is currently to submit the patient to partial lymph
node dissection. This does not avoid significant side effects. It
seems that it is possible to spare some patients from lymph
node dissection by detecting those who have a very low risk
to harbour metastases in non-SNs. A recent study on 814
patients with breast cancer less than 3 cm diameter [10]
revealed 35.1% positive SNs. Subsequent axillary dissections
revealed tumours in non-SNs in 188 (65.7%) of these patients.
Tumour exhibiting high nuclear grading, ER-, PR-, Erb-2/neu
overexpression, lymphovascular invasion, increasing tumour
size, multiple positive SNs, and macrometastatic size in SNs
(>2mm) were all significantly correlated with non-SN meta-
stases. Multivariate analysis showed that tumour size, the
number of positive SNs, and the metastatic size in SNs were
independent factors predicting the presence of positive non-
SNs. As for melanoma, it seems that it will be possible to
restrict lymph node dissection in selected patient population.
Other indications were investigated: colon cancer, vulva
and penis carcinoma, thyroid cancer, lung cancer, gastric car-
cinoma, pancreas carcinoma, and cervix cancer.
In this issue of Annals of Oncology, Barranger et al. [11]
explored SNB in 23 patients with various stages of cervical
cancer who were first submitted to SNB and thereafter to lym-
phadenectomy associated to appropriate surgery. No false
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negative SNB was found in the patients with early cervix car-
cinoma—stageIA, IB1—whilst nearly 43% of locally
advanced cervix carcinoma had false negative SN.
These results underline the fact that the concept of SNB
holds true in primary high risk cancers but not in locally
advanced cancers where alterations in the lymph flow and
lymph node biology are expected.
Taken together, the results of the extensive studies in mela-
noma and breast cancer indicate that SNB is a valuable tool
for early diagnosis of micrometastases, with a clear prognostic
value. However, up to now, there is no evidence that SNB
improves the overall survival. It is hoped that SNB patients
will be found to benefit the most from adjuvant treatment
because of the small burden of putative systemic micrometa-
stases. It remains to be studied whether this can be applied to
other cancers such as cervix carcinoma where HPV virus
immunisation seems to be a potential treatment.
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